Introduction
============

Idiopathic trigeminal neuralgia and trigeminal neuropathic pain are severe and constant orofacial pain syndromes. Because of such pain, the patient\'s quality of life is remarkably decreased. Idiopathic trigeminal neuralgia is caused by sensory nerve root compression and characterized by sudden onset of stabbing pain attacks [@B1], [@B2]. In contrast, trigeminal neuropathic pain is associated with trigeminal nerve injury, leading to chronic pain such as burning and aching [@B3], [@B4]. Although antidepressants and anticonvulsants are effective in palliating idiopathic trigeminal neuralgia, these drugs have little effect on the palliation of trigeminal neuropathic pain [@B5].

Neuropathic pain including trigeminal neuropathic pain indicates mechanical and heat hyperalgesia, and enhances heat sensitivity. A number of peripheral nerve injury models have been developed, such as spinal nerve ligation (SNL) model [@B6], chronic constriction nerve injury (CCI) model [@B7] and partial sciatic nerve injury (PSL) model [@B8]. However, only a few animal models in the trigeminal system have been reported. Trigeminal neuropathic pain models have been developed in which the infraorbital nerve (ION) [@B5], [@B9] or inferior alveolar nerve (IAN) [@B10] is injured. These models demonstrate mechanical allodynia and heat hyperalgesia.

Transient receptor potential vanilloid 1 (TRPV1) has been identified as a capsaicin-, heat- and proton-sensitive ion channel [@B11]-[@B13]. TRPV1 is highly expressed in small-diameter primary sensory neurons in dorsal root ganglia (DRG) and trigeminal ganglia (TG) [@B11], [@B13]. TRPV1 is reported to be involved in inflammation [@B14], cancer [@B15], [@B16] and neuropathic pain [@B17]-[@B19]. In orofacial pain, TRPV1 is reported to be involved in tooth pulp inflammation [@B20], [@B21], temporomandibular disorders (TMD) [@B22], oral cancer [@B23] and IAN injury pain [@B24]. These findings indicate that TRPV1 participates in neuropathic pain and may be involved in trigeminal neuropathic pain. Moreover, analysis of TRPV1 expression may contribute to the development of therapeutic drugs and methods for treating trigeminal neuropathic pain.

In this study, to examine the mechanisms of trigeminal neuropathic pain, we validated a partial infraorbital nerve ligation (pIONL) model by the evaluation of changes in nociceptive responses to mechanical and heat stimuli. In addition, we investigated the changes of TRPV1 expression in TG neurons.

Materials and Methods
=====================

Experimental animals
--------------------

Twenty-seven male Sprague-Dawley rats (SLC, Hamamatsu, Japan) weighing 150-350 g were used in this study. All procedures for animal care were approved by the Animal Management Committee of Matsumoto Dental University (permission No. 177). All animal experiments were performed in compliance with the Guidelines for Proper Conduct of Animal Experiments, established by the Science Council of Japan, and the guidelines of the International Association for the Study of Pain [@B25].

Partial infraorbital nerve ligation model
-----------------------------------------

A partial ION ligation model was produced as previously described [@B5]. In brief, the ION was partially ligated using 6-0 silk according to Seltzer\'s model [@B8]. For a control, a sham operation was performed identically except that the nerve was not ligated. All operations were performed aseptically, no antibiotics were administered and all rats recovered uneventfully. After surgery, the rats were given laboratory chow and tap water ad libitum under conventional laboratory conditions [@B5].

Behavioral testing
------------------

The time courses of mechanical and heat sensitivity and the effects of antagonist on behavioral experiments were determined in a partial ligation of the ION (pIONL) group and a sham operation group (Sham). Rat whiskers were cut with scissors the day before experiments. Animals were allowed to acclimate to their surroundings for 10-15 minutes before testing. During the assessment of mechanical and heat sensitivity, animals were restrained around the trunk with a towel to calm them and treated gently during the experiments [@B5].

Assessment of mechanical sensitivity
------------------------------------

Mechanical sensitivity of rat\'s vibrissal pad (VP) was tested as previously described [@B5]. von Frey filament (26 g; North Coast Medical Inc., Morgan Hill, CA) was applied to the VP. The frequency of nociceptive response (head withdrawal or vocalization) was measured from 5 trials. For each trial, the filament was applied at 5-second intervals. The nociceptive threshold was defined as the minimum force needed to evoke nociceptive responses in at least 60% of the trials [@B26]. The same procedure was performed on days 2, 4, 6, 8, 10, 12, 14, 21 and 28 after pIONL.

Assessment of heat sensitivity
------------------------------

The thermal response was assessed by application of heat stimuli to VP using a stimulator equipped with a thermal probe (THERMAL STIMULATOR UDH-300s, UNIQUE MEDICAL CO., LTD., Tokyo, Japan). During the assessment of heat sensitivity, the glycerol (Sigma) was applied to VP to increase thermal conductivities. Briefly, the thermal probe (diameter: 5 mm) was placed manually on the VP, and the probe temperature was increased at a rate of 1.0ºC/sec to a maximum of 58ºC (cut-off), which was established in order to prevent tissue damage. Animals were confined so as not to withdraw or flick their snouts when their VP was placed on the thermal probe maintained at room temperature before testing. Withdrawal threshold was defined as the temperature at which animals withdrew (head withdrawal or vocalization) their VPs. Withdrawal temperature was measured from 5 trials. For each trial, the filament was applied at 5-second intervals.

Animals were tested before pIONL to assess basal levels. The same procedure was performed on days 2, 4, 6, 8, 10, 12, 14, 21 and 28 after pIONL.

Peripheral administration of TRPV1 antagonist
---------------------------------------------

The effects of the TRP channel antagonist on behavioral experiments were studied 25-28 days after ligation. The TRP channel antagonist capsazepine (Biomol International, Plymouth Meeting, PA) was dissolved in 100% dimethylsulfoxide (DMSO, Sigma) [@B26]. The EC50 value for capsazepine against TRPV1 on the inward currents was 7.8 μM in oocyte [@B27]. The peripheral administration of capsazepine and the concentration used in this study have been proven to be effective in previous studies [@B16]. Fifty μL of capsazepine was subcutaneously administered in small doses at a few separate bilateral VP locations in various directions to make sure that the drugs would reach all over the VP. In control experiments, 50 μL of 100% DMSO was administered. Withdrawal responses were measured 30 minutes after capsazepine injection. Before the administration of capsazepine or DMSO, animals were tested to assess the basal level of withdrawal responses.

Immunohistochemistry
--------------------

TG were fixed and processed for immunohistochemistry as in a previous study [@B28]. Animals were perfused with cold 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). For the immunohistochemistry of TG, rabbit polyclonal antiserum against synthetic rat TRPV1 (Trans Genic, Kumamoto, Japan) was used after dilution at a concentration of 1:50 in 0.1 mol/L PBS containing 4% normal goat serum and 0.3% Triton-X 100 (Sigma). Sections were reacted with the reagent for 2 days at 4°C. After rinsing, species-directed secondary antibodies (Alexa Fluor 488-conjugated goat anti-rabbit IgG; 1:500, Invitrogen, Carlsbad, CA) were applied to the sections (120 min). After being rinsed with 0.1 M PBS, the sections were cover-slipped in mounting medium (Diagnostic BioSystems Pleasanton, CA, USA) and examined under a fluorescence microscope equipped with a digital camera. No specific labeling was observed in the absence of a primary antibody.

The numbers and sizes of TRPV1-positive cells were automatically counted and measured using the computer-assisted imaging analysis system Image J [@B29]. The TRPV1-positive cells were arbitrarily classified by cell diameter into 3 groups (\< 20, 20-30, and \> 30 μm) [@B23]. The ratios of TRPV1-positive cells in each animal were calculated by the following formula: (total number of positive cells in 5 sections of TG/total number of all cells in 5 sections of TG) × 100. The calculation was performed for each group of cells classified by cell size [@B5].

Statistical analysis
--------------------

Data are expressed as mean ± standard error (S.E.). To determine the significance of differences in mechanical sensitivity and heat sensitivity (Fig. [1](#F1){ref-type="fig"} and Fig. [2](#F2){ref-type="fig"}) among Sham and pIONL groups, two-factor repeated-measure analysis of variance (ANOVA) was performed. The Huynh-Feldt ε correction was used to evaluate *F* ratios for repeated measures involving more than one degree of freedom. Holm-corrected *post hoc* Welch test was applied (10 hypotheses between Sham and pIONL group at each day in Fig. [2](#F2){ref-type="fig"}; 6 hypotheses, pre vs. DMSO, DMSO vs. 10 pmol/50 μL of capsazepine and DMSO vs. 100 pmol/50 μL of capsazepine in each operation in Fig. [2](#F2){ref-type="fig"}).

Welch test was performed to determine whether the ratios (Fig. [4](#F4){ref-type="fig"}A) and the major axis (Fig. [4](#F4){ref-type="fig"}B) of TRPV1-positive cells in TG were significantly different among Sham and pIONL groups. Fisher\'s exact test was performed to determine whether the ratios of TRPV1-positive cells classified by cell size were significantly different among Sham and pIONL groups (Fig. [4](#F4){ref-type="fig"}C).

All computations were performed with the statistical program R [@B30], and type II sum of squares was calculated with the package \'car\'. Values with *p*\< 0.05 were considered as significantly different.

Results
=======

Change in mechanical sensitivity
--------------------------------

In the Sham group, the frequency of nociceptive responses showed no significant changes during the experimental period. In the pIONL group, the frequency of nociceptive responses was significantly increased at days 6, 14, 21 and 28 after pIONL compared with that in the Sham group, indicating the development of mechanical allodynia (Fig. [1](#F1){ref-type="fig"}A).

Change in heat sensitivity
--------------------------

In the Sham group, withdrawal temperature showed no significant changes during the experimental period. In the pIONL group, withdrawal temperature was significantly decreased at days 4, 10, 21 and 28 after pIONL compared with that in the Sham group, indicating the development of heat hyperalgesia (Fig. [1](#F1){ref-type="fig"}B).

Effect of capsazepine on mechanical and heat hyperalgesia
---------------------------------------------------------

We examined the effect of the TRP channel antagonist capsazepine. In the Sham group, peripheral administration of DMSO and capsazepine induced no significant changes in both mechanical and heat sensations (Fig. [2](#F2){ref-type="fig"}A and B). In the pIONL group, peripheral administration of capsazepine induced no significant changes in the mechanical hyperalgesia (Fig. [2](#F2){ref-type="fig"}A). In contrast, capsazepine revealed partial inhibition of heat hyperalgesia in a dose-dependent manner. Moreover, 100 pmol/50 μL of capsazepine reversed heat sensation to the sham level (Fig. [2](#F2){ref-type="fig"}B). Peripheral administration of vehicle (100% DMSO) showed no effect in both mechanical and heat sensations.

Expressions of TRPV1 in trigeminal ganglia
------------------------------------------

TRPV1-positive cells were intensely stained and were easily distinguished from the nonpositive cells (arrows in Fig. [3](#F3){ref-type="fig"}). We arbitrarily classified the cell sizes according to the frequency distribution of the ganglion cells and data in the literature [@B23].

At 28 days after pIONL, the ratios of TRPV1-positive cells in all TG were not significantly different between Sham and pIONL groups (Fig. [4](#F4){ref-type="fig"}A). In contrast, the mean of the major axis in the pIONL group was significantly longer than that in the Sham group (Fig. [4](#F4){ref-type="fig"}B). The ratio of the TRPV1-positive large-diameter-cell group (\> 30 μm) in TG significantly increased in the pIONL group (Fisher\'s exact test, *P* \< 0.001). In addition, in both Sham and pIONL groups, TRPV1-positive large-diameter-cell numbers were higher than in any cell groups (Fig. [4](#F4){ref-type="fig"}C).

Discussion
==========

This study aims to investigate whether withdrawal temperature by heat stimuli and TRPV1 expression in TG neurons change using a trigeminal pain model (*i.e.* pIONL model). We found that withdrawal temperature was significantly decreased in the pIONL group, and that capsazepine recovered the heat hyperalgesia. In addition, we found that the ratio of TRPV1-positive cells was increased in large neurons in TG by pIONL. These results suggest that TRPV1 expression in large neurons participated in the development and maintenance of heat hyperalgesia by trigeminal neuropathic pain.

In this study, we observed mechanical allodynia and heat hyperalgesia using a pIONL model (Fig [1](#F1){ref-type="fig"}). This pIONL model provides consistent and reproducible persistent hyperalgesia, which was shown in neuropathic pain patients. In this study, the determination of withdrawal temperature would promote more research into orofacial pain.

We evaluated the potential role of TRPV1 in chronic pain conditions by examining the anti-hyperalgesic activity of a TRP channel antagonist, capsazepine, in trigeminal neuropathic pain. Capsazepine has been shown to inhibit capsaicin-induced TRPV1 activation competitively across species *in vitro* [@B31]. Capsazepine inhibited mechanical and heat hyperalgesia associated with a cancer pain model in rat [@B16]. In this study, 100 pmol/50 μL of capsazepine inhibited heat hyperalgesia but not mechanical allodynia (Fig. [2](#F2){ref-type="fig"}). The anti-hyperalgesic effect of capsazepine in this study was in the same dose range as that in rat cancer pain models [@B16]. In PSL neuropathic pain model, capsazepine recovered mechanical hyperalgesia in the guinea pig but not in the rat [@B32]. These studies suggest that TRPV1 participates in the development of mechanical hyperalgesia or allodynia in neuropathic pain animal models and demonstrate species differences as a potential factor influencing the functional contribution of TRPV1. Therefore, the possible involvement of TRPV1 receptor in the heat hyperalgesia in the pIONL model is suggested.

In this study, TRPV1-positive large-diameter cells in TG increased and medium- and small-diameter cells decreased strikingly by pIONL (Fig. [4](#F4){ref-type="fig"}C), although there was no significant difference in the ratio of TRPV1-positive cells between pIONL and control animals (Fig. [4](#F4){ref-type="fig"}A). We consider that our results may explain the behavioral data that pIONL induced sustained mechanical allodynia and heat hyperalgesia. In other pain models such as nerve injury, cancer and inflammation, the ratio of TRPV1-positive cells in large neurons was also increased. In nerve injury model animals, TRPV1 was expressed *de novo* in myelinated A-fiber in mouse DRG neurons after PSL [@B18]. Similarly, after L5 and L6 SNL, there was a dramatic shift in the size distribution of TRPV1-positive neurons towards large-diameter cells, although the proportion of TRPV1-positive DRG neurons was not changed [@B33]. Although the relationship between DRG cell body diameter and class of afferent is not exact, our data are consistent with these previous reports that TRPV1 is expressed in A-fiber cell bodies *de novo* after nerve injury. In cancer pain model animals, the ratio of TRPV1-positive cells was increased in the large-cell groups in mouse DRG [@B15], rat DRG [@B16] and rat TG [@B23]. However, there was no significant difference in the ratio of total TRPV1-positive cells in rat DRG [@B16]. In inflammation, the ratios of TRPV1-positive cells in small- and medium-sized DRG neurons were increased. These TRPV1-positive neurons were myelinated Aδ-fibers in rat DRG [@B14]. These findings support our assumption that the aberrant TRPV1 expression in TG neurons and the structural plasticity of myelinated A-fiber neurons are important mechanisms causing mechanical allodynia and heat hyperalgesia in trigeminal neuropathic pain. Originally, TRPV1 expression is restricted to small- to medium-sized DRG neurons [@B34], suggesting that TRPV1 is a polymodal nociceptor with unmyelinated C-fibers and some thinly myelinated fibers. Moreover, the large DRG neurons that innervate Aβ-afferents are not normally associated with nociception [@B15]. In pathological conditions such as nerve injury, cancer and inflammation, therefore, TRPV1 may be upregulated in A-fibers such as Aβ and Aδ neurons and may be activated by noxious heat stimuli through increased TRPV1.

Furthermore, it is shown that TRPV1 expression in "uninjured" neurons was increased in the DRG and TG nerve injury. For instance, in unilateral L5 SNL animals, the number of TRPV1-positive cells was increased in undamaged L4 DRG, and the expression of TRPV1 mRNA was increased in small- and medium-sized cells in undamaged L4 DRG neurons [@B19]. Similarly, after L5 SNL, TRPV1-positive cells were increased in uninjured A-fiber neurons in particular, and were greatly reduced in all damaged fibers in rat DRG [@B17]. Moreover, in a trigeminal neuropathic pain model including the inferior alveolar nerve and mental nerve injury (IAMNT) model, the expression of TRPV1 was increased in the uninjured TG neurons [@B24]. From these reports, we assumed that increased TRPV1 expression in uninjured nociceptive neurons plays an important role in the mechanical allodynia and heat hyperalgesia in the pIONL model.

In contrast, the mechanisms of TRPV1-mediated mechanical allodynia or hyperalgesia remain to be elucidated. Although the role of TRPV1 in mechanical hypersensitivity has been controversial, it is reported that capsazepine attenuates mechanical allodynia or hyperalgesia associated with neuropathy [@B17], cancer [@B16] and inflammation [@B35]. These results suggest that the upregulation and/or sensitization of TRP channel receptors other than TRPV1 may also play important roles in mechanical allodynia and heat hyperalgesia. Similarly, recent studies suggested that other TRP channels including TRPV2, TRPV3, TRPV4 and TPPA1 mediate mechanosensation and/or thermal sensation. TRPV2, a TRPV1 homologue, is activated by a very high-threshold heat temperature (\> 52ºC), suggesting that TRPV2 acts as a high-threshold temperature sensor in Aδ nociceptors [@B28], [@B36]. TRPV2 was upregulated in the eccentric exercise (ECC)-induced muscle pain model [@B26], and capsazepine attenuated mechanical hyperalgesia associated with this model. TRPV3 and/or TRPV4 in keratinocytes might participate in temperature sensation [@B37]-[@B39]. In addition, mechanosensation is defective in mice lacking TRPV4 [@B40]. TRPA1 has been identified as a cold-sensitive ion channel, was highly expressed in DRG and TG, and was co-expressed with TRPV1 [@B13], [@B41]. Both TRPV1 and TRPA1 are reported to mediate capsaicin- and mustard oil-induced mechanical hypersensitivity in a masseter muscle pain model [@B22]. In DRG from CCI rats, TRPA1 and TRPV2 mRNA were slightly but significantly increased after nerve injury [@B42]. In addition to TRPV1, therefore, TRPV2, TRPV3, TRPV4 and TRPA1 may be involved in mechanical allodynia and heat hyperalgesia in our model.

In conclusion, the increase of TRPV1-positive large-diameter cells in the trigeminal sensory system may play an important role in developing and maintaining heat hyperalgesia induced by trigeminal neuropathic pain. Moreover, TRPV1 might be an effective therapeutic target for orofacial pain syndrome associated with trigeminal nerve injury.
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![Time course of the changes in mechanical (A) and heat (B) sensitivities in vibrissal pad after pIONL. Vibrissal pads ipsilateral to nerve injury and sham operation were stimulated with noxious stimuli. Open circles, Sham group (n = 5); closed circles, pIONL group (n = 5). *P* values were calculated by two-factor repeated-measure ANOVA corrected with Holm method (10 hypotheses). \* *P* \< 0.05 and \*\* *P* \< 0.01 (Sham vs. pIONL).](ijmsv09p0690g01){#F1}

![Effects of TRPV1 antagonist capsazepine (CPZ) on behavioral experiments. At 25-28 days after pIONL, none (pre), 50 μL of DMSO, 10 pmol/50 μL of CPZ and 100 pmol/50 μL of CPZ were intraperitoneally injected. After 30 min, mechanical (A) and heat (B) sensitivities in vibrissal pad were examined. *P* values were calculated by two-factor repeated-measure ANOVA corrected with Holm method (6 hypotheses). \* *P* \< 0.05, \*\* *P* \< 0.01 (pre vs. DMSO, DMSO vs. 10 pmol/50 μL of CPZ and DMSO vs. 100 pmol/50 μL of CPZ in each operation).](ijmsv09p0690g02){#F2}

![Fluorescent photomicrographs of TRPV1-immunoreactive cells in TG on sham-operated side (A), nerve ligation side (B) and in the absence of a primary antibody. (C). Arrows indicate TRPV1-positive neuron. Bar, 100 μm.](ijmsv09p0690g03){#F3}

![Proportion of TRPV1-positive neurons in TG neurons in the pIONL group (n = 4) and the Sham group (n = 4). (A) The means of ratios of TRPV1-positive cells to all cells in TG neurons. *P* = 0.952 (Welch test). (B) The mean of the major axis of TRPV1-positive cells. Total TRPV1-positive cell numbers are indicated in parentheses. *P* \< 0.001 (Welch test). (C) Ratios of TRPV1-positive cells classified by cell size (C). Cells were classified into 3 groups (\< 20 μm, 20 to 30 μm, \> 30 μm) by the major axis of cells. The ratios of TRPV1-positive cells in each group to total TRPV1-positive cell number are shown. *P* \< 0.001 (Fisher\'s exact test).](ijmsv09p0690g04){#F4}
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